Cytogel is pioneering a novel approach to pain management through the development of endomorphin-based therapies, specifically focusing on their lead compound, CYT-1010. This innovative drug targets the endomorphin receptors in the central nervous system, providing effective pain relief while minimizing the adverse effects commonly associated with traditional pain medications, such as opioids. Clinical studies have demonstrated that CYT-1010 not only offers significant analgesic activity but also exhibits reduced addiction potential and a lower risk of respiratory depression. The compound has shown impressive anti-inflammatory properties and has been found to enhance recovery times post-surgery, marking it as a transformative option for patients suffering from moderate to severe pain.

In addition to their lead compound, Cytogel is advancing hydrogel technology for drug delivery, which enhances the efficacy of their therapeutic agents. These advanced polymer systems are designed to improve the kinetic profiles of drugs, allowing for timed, tissue-specific, and pH-sensitive release. This technology holds promise for various applications, including coatings for drug-eluting stents in interventional cardiology, potentially leading to better patient outcomes. By integrating these innovative drug delivery methods with their endomorphin therapies, Cytogel aims to address the pressing challenges in pain management and improve the overall treatment landscape for patients.

United States

Cytogel is a clinical stage bio-pharmaceutical company developing first in class drug candidates from the novel endomorphin family of molecules, that target key pain pathways and alleviate pain. This groundbreaking approach is backed by new technology to deliver treatment to people in pain. Learn how we’re reinventing pain management.

Cytogel

Company Details